This website uses cookies

Read our Privacy policy and Terms of use for more information.

Presented by
Closing Bell: the Daily Rip index table Click to expand Closing Bell →

The selling never really let up on Tuesday, it just changed its reason as the day went on. By the close the market had stopped trading the economy and started trading the wait for one earnings report. Nvidia beat, with a new CEO on the throne.

The S&P 500 fell 1% and the Dow fell 1.6%, while the Nasdaq went flat and small caps fell 1.4%. None of the 11 sectors finished green. Financials were the weak spot, down 1.9%, Energy fell the least at 0.5%, and bitcoin dropped 1.5%.

The Commerce Department reported October retail sales up 0.2%, and the control group that feeds into GDP rose 0.6%, about double the forecast. The 10-year Treasury yield, the rate that prices mortgages and corporate borrowing, climbed to about 5.15%, and traders repriced the Fed path ahead of Wednesday’s FOMC minutes.

Nvidia owned the evening, first as the excuse for the software route, then with a beat and a $130 billion guide that carried the neoclouds with it. The AI labs spent the day selling the scare ahead of Anthropic’s pricing tomorrow, L3Harris spent it answering for one router in Arkansas, and SELLAS’ leukemia vaccine turned a halted biotech into the loudest tape of the day.

Today's Briefing:

  • After The Bell: Nvidia beats, guides to $130B, China shipments back in print

  • Stocks: the labs sell the scare, one router grounds America, SELLAS' vaccine hits

  • What's Trending Now on Stocktwits

Market heat map: the S&P 500 by sector Click to expand the live heat map →

AFTER THE BELL
Nvidia Beat the Bar and Raised It

Nvidia reported third-quarter results after the close on Tuesday, its first earnings release since Jensen Huang resigned as chief executive last week. Colette Kress, the chief financial officer now serving as interim CEO, ran the report, and the numbers cleared every estimate the Street had published. Thousands of Stocktwits users waited for the earnings call screaming at each other. Ah, another beautiful day at Stocktwits. 📈

The RIP: $NVDA ( ▼ 2.51% ) rose 3% after hours. Revenue was $115.8 billion against a $109.1 billion estimate, and adjusted earnings were $2.68 a share against $2.48 expected. Data Center revenue was $107.6 billion, up 110% from a year ago. The fourth-quarter guide is $130 billion, above the $125.2 billion estimate.

Gross margin was 74.8%, guided down to 71% to 72% next quarter on memory costs. Net income was $65.3 billion. The neoclouds followed the stock higher, CoreWeave up 2% and Nebius up 3%, because Nvidia's guide is their order book.

As for the Singapore affair: $2.4 billion of Hopper products shipped to China, but Nvidia has not reported revenue to Singapore, for a year. So how did Huang and Huang trade chips? Michael Burry wrote that he suspects accounting hid the trail: Nvidia dropped billing-address reporting after Singapore booked $10.2 billion in the July 2025 quarter, and the new headquarters counting lifted fiscal 2025 China revenue to $25.0 billion. “Clean compliance, perhaps too clean,” he wrote, conceding no evidence of a misstatement. He is short the stock. Culper alleges over 20% of compute revenue still traces to China.

China-headquartered customers still booked $11.05 billion this quarter. Supply and capacity commitments hit $390 billion, up from $279 billion in July, which is what a company signs when it expects to stay sold out. 💰

The board said it does not plan to reinstate Huang, who posted Tuesday morning that he would be honored to come back. He resigned after admitting to an affair with Alice Huang, the former Megaspeed executive US intelligence officials suspect of spying for Beijing. The board’s investigation is still open, and no permanent successor has been named. 🎙️

SPONSORED BY PRENETICS GLOBAL LIMITED
Prenetics' IM8: $220–230M Revenue Guidance in Year Two. What Comes Next?

David Beckham co-founded it. The NBA is partnering with it. And you can follow the public company behind it.

Meet IM8, the premium nutrition and longevity brand owned by Prenetics (Nasdaq: PRE). Launched in December 2024, it reached a ~$251 million annualized revenue run-rate within 20 months.

Ahead of tomorrow's earnings:

  • $220–230 million FY26 guidance

  • More than $400 million in projected IM8 revenue for 2027

  • Official Nutrition Partner of the NBA in nine markets

  • Care Bears by IM8, a 10-year global partnership with Authentic Brands Group

Join Prenetics' earnings event on Stocktwits tomorrow. Follow $PRE.

*3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here.

Disclaimer: This is a paid advertisement. For informational purposes only — not investment advice or a solicitation to buy or sell securities. Forward-looking statements are subject to risks and uncertainties; actual results may differ materially.

STOCKS
Build the Bomb, Sell the Bomb Shelter

The FBI warned Friday that hackers have weaponized ARTEX, a framework running on Claude and ChatGPT, reaching privileged access in under three hours. The framework came back into the news today, after Google's threat team said Monday, agentic hacking reached an inflection point. Anthropic prices on Wednesday. Am I the only one who is freaked out?

The RIP: Anthropic prices Wednesday at $70 to $78, a $916 billion to $1.02 trillion valuation, off a filed $17 billion third quarter. Hacking and cyber threats may have always been part of the investing playbook.

In August 2025 Anthropic reported "vibe hacking," one criminal, 17 organizations, and closed a $13 billion raise six days later. In November 2025 came the first AI-orchestrated espionage campaign, some 30 targets, no victims named. Security researcher Kevin Beaumont was skeptical; analyst Daniel Card called it "marketing guff."

Then came the bomb shelter, on sale: Claude Code Security dropped February 2026, then Glasswing in April. And who could forget when Mythos was released gated to 11 partners massive corporations at $40 million to $120 million a contract, per Bloomberg. Sam Altman himself called out Anthropic for this on a podcast: "We have built a bomb, we are about to drop it on your head. We will sell you a bomb shelter for $100 million." In September, ANT conceded the attacks ran on phishing, stolen passwords and unpatched servers. Old stuff, not Terminator 2 stuff. 💣

Software Smoftware

Software took the day's worst beating Tuesday, on the eve of the eve of the ANT IPO. Salesforce fell 10% to $195, its worst day since May 2024 and the worst stock in the Dow, with no announcement or downgrade behind it. ServiceNow fell with it. Microsoft fell 2%, the software ETF 3%. 📉

Two fears did the work. First, supply: a trillion-dollar Anthropic listing gives every portfolio a new AI name to own. The money has to come from somewhere. Second, the seat model: agents do the work per-seat software charges for. A week of warnings about agents hacking at machine speed doubles as proof the agents work. 🤖

Lets review: On Friday one router in El Dorado, Arkansas, grounded flights nationwide for nearly five hours and forced 18,000 cancellations. On Monday a software bug in Chase's hardware delayed bank transactions, and Zelle delays made it look wider. United halted departures on a separate computer problem. On Tuesday the NSA's network went down, no cyberattack was blamed. DHS Secretary Markwayne Mullin blamed aging systems: "98% certainty this isn't a cyberattack."

Everyone is on edge, but sometimes everyone just sucks at updating software that’s old and complex.

Five rounds of warnings in fifteen months, each one followed by a raise, a product or a filing. The failures that grounded planes and froze money ran on a router, a software bug and old copper. Buckle up, the final round is tomorrow, and who knows when OpenAI is dropping their IPO after. 🛡️

STOCKS
The Router That Grounded America Has a Ticker

Speaking of the FAA grounding… The Transportation Department blamed Friday's nationwide ground stop on a router that L3Harris installed at a Federal Aviation Administration site in El Dorado, Arkansas. The company runs the FAA's communications network under a long-term contract. Transportation Secretary Sean Duffy briefed senators on the failure on Tuesday. ✈️

The RIP: $LHX ( ▼ 1.43% ) fell 4% on Monday after Duffy named the company, then fell 1% more on Tuesday to $259. The new router flooded the network with 1,000 connection attempts every few seconds, destabilized radar and radio at 17 of 22 en route centers, and forced a ground stop that canceled more than 18,000 flights.

Duffy has not decided whose fault it is. Like Anthropic and AI fear, he of course used it as a call to raise money for his enterprise, not without warrant. He asked Congress for $50 billion to rebuild air traffic control, up from $30 billion a week earlier. He said investigators are working out whether it was installer error by L3Harris or just a faulty router. He also said: "I'm stuck with L3 Harris, who owns this network." Yeesh.

The conversion program covers 3,648 routers. Four hundred are installed and 69 are live. The Cisco routers the project will rip out date from 2001 and were due for replacement in 2006. 💸

STOCKS
SELLAS' Vaccine Cut Death Risk by 41%

SELLAS Life Sciences announced Tuesday that galinpepimut-S, its experimental cancer vaccine, met the main goal of the Phase 3 REGAL trial in acute myeloid leukemia. The vaccine is a maintenance therapy, given to patients in their second or later remission who cannot get a stem cell transplant. The stock was halted before the open, ripping more than 300% overnight.

Stocktwits die hard investors would have told you it was always going to do that. Of the top ten picks as voted by the community earlier in the year, SLS is by far the under $10 winner. 🧬

The RIP: $SLS ( ▲ 2.92% ) closed up 156% at $19 and then fell 15% after hours to $16. Patients on the vaccine lived a median of 24.0 months, against 14.7 months on the best available treatment. The hazard ratio was 0.59, a 41% lower risk of death, in a trial of 126 patients.

The trial hit its prespecified 80th event last month, the milestone that triggered the final analysis. SELLAS licensed the vaccine from Memorial Sloan Kettering, and it trains the immune system on WT1, a protein found across several cancers. The company said the treatment was generally well tolerated, with no new safety concerns and mostly mild or moderate reactions at the injection site. 💉

The next step is a meeting with the FDA. SELLAS said it expects to meet with the agency to discuss an accelerated filing strategy, with a Biologics License Application planned for the first half of 2027. Nothing is approved. Nothing has been filed. The p-value was 0.035, significant and not a landslide.

The stock told the careful version all day. It opened at $24, printed a $25 high, and sold down into the close on 117 million shares, about 19 times its normal pace. Martin Shkreli called the results 'sketch' in a post. The community stayed bullish, and one poster put the bull case plainly: "What stands out to me isn't simply that the trial achieved statistical significance. It's the magnitude of the reported survival benefit in a population with a serious risk of relapse and death."

One trial, one very large candle. 🕯️

POPS & DROPS
Trending Now

UnitedHealth fell after CMS proposed the CRUSH rule, which would expand Medicare Advantage audits and let the agency recover an estimated $9 billion a year in unsupported diagnosis payments, with Mizuho naming UnitedHealth and Humana the most exposed. Community is bullish.

Nebius rose after hours as Nvidia's $130 billion fourth-quarter guide read straight through to the companies that rent out its chips, with CoreWeave up 2% on the same print. Community is bullish.

MARA fell after it priced $185 million of senior secured notes due 2032 at 8.750%, a coupon that shows what capital costs a bitcoin miner right now. Community is bullish.

SPONSORED

Stop Drowning In AI Information Overload

Your inbox is flooded with newsletters. Your feed is chaos. Somewhere in that noise are the insights that could transform your work—but who has time to find them?

The Deep View solves this. We read everything, analyze what matters, and deliver only the intelligence you need. No duplicate stories, no filler content, no wasted time. Just the essential AI developments that impact your industry, explained clearly and concisely.

Replace hours of scattered reading with five focused minutes. While others scramble to keep up, you'll stay ahead of developments that matter. 600,000+ professionals at top companies have already made this switch.

*3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here.

Get In Touch 📬

Want to see some change? Respond to this email and reach me, Kevin Travers, with feedback. Follow me on Stocktwits. Send me charts and ideas! Refer a friend for this quarter’s edition of The RIP Forecast 😎

Terms & Conditions 📝

Securities Disclaimer: STOCKTWITS IS NOT A TAX ADVISOR, BROKER, FINANCIAL ADVISOR OR INVESTMENT ADVISOR. THE SERVICE IS NOT INTENDED TO PROVIDE TAX, LEGAL, FINANCIAL OR INVESTMENT ADVICE, AND NOTHING ON THE SERVICE SHOULD BE CONSTRUED AS AN OFFER TO SELL, A SOLICITATION OF AN OFFER TO BUY, OR A RECOMMENDATION FOR ANY SECURITY. Trading in such securities can result in immediate and substantial losses of the capital invested. You should only invest risk capital and not capital required for other purposes. You alone are solely responsible for determining whether any investment, security or strategy, or any other product or service, is appropriate or suitable for you based on your investment objectives and personal and financial situation. You should also consult an attorney or tax professional regarding your specific legal or tax situation. The content is to be used for informational and entertainment purposes only and the service does not provide investment advice for any individual. Stocktwits, its affiliates and partners specifically disclaim any and all liability or loss arising out of any action taken in reliance on content, including but not limited to market value or other loss on the sale or purchase of any company, property, product, service, security, instrument, or any other matter. You understand that an investment in any security is subject to a number of risks and that discussions of any security published on the Service will not contain a list or description of relevant risk factors. In addition, please note that some of the stocks about which content is published on the service have a low market capitalization and/or insufficient public float. Such stocks are subject to more risk than stocks of larger companies, including greater volatility, lower liquidity and less publicly available information. Read the full terms & conditions here. 🔍
Author Disclosure: The author of this newsletter does not hold positions in any of the securities or assets mentioned. 📋